05 April 2022: Original Paper
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation
Okjoo Lee 1ABCDEF , Jinsoo Rhu 1ABCDE* , Gyu-Seong Choi 1ABCDE , Jong Man Kim 1CD , Kyunga Kim 2CD , Jae-Won Joh 1CDDOI: 10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
Table 2 Postoperative outcomes.
| Characteristics | Statin non-user (n=334) | Statin user (n=52) | P-value |
|---|---|---|---|
| Donor fatty change (%) | |||
| Macroscopic | 6.99±5.78 | 8.50±7.01 | 0.026 |
| Microscopic | 9.29±8.00 | 10.20±7.56 | 0.293 |
| Graft weight (g) | 699.10±128.47 | 727.96±120.77 | 0.064 |
| GRWR | 1.03±0.22 | 1.04±0.22 | 0.683 |
| Operation time (min) | 563.89±113.08 | 553.02±105.91 | 0.455 |
| Cold ischemic time (min) | 88.90±29.18 | 102.40±64.96 | 0.981 |
| Warm ischemic time (min) | 35.13±14.47 | 33.31±11.72 | 0.492 |
| Tumor | |||
| Number | 2.44±2.73 | 1.75±1.08 | 0.109 |
| Size (largest, cm) | 3.03±1.99 | 2.58±1.60 | 0.094 |
| Pathologic (Edmonson grade) | 2.02±0.50 | 1.88±0.55 | 0.080 |
| Microvascular invasion | 169 (50.60%) | 23 (44.23%) | 0.393 |
| Postoperative laboratory findings (at 7 days after LT) | |||
| Peak AST (U/L) | 368.02±399.98 | 463.56±507.85 | 0.012 |
| Peak ALT (U/L) | 395.71±433.17 | 461.56±363.76 | 0.015 |
| Peak total bilirubin (mg/dL) | 4.10±4.54 | 4.25±6.26 | 0.359 |
| Pear prothrombin time (INR) | 2.65±0.67 | 2.52±0.63 | 0.098 |
| Acute rejection episode | 38 (11.38%) | 11 (21.15%) | 0.049 |
| Complication (Clavien-Dindo) | 167 (50.0%) | 24 (46.15%) | 0.606 |
| I | 11 | 1 | |
| II | 44 | 10 | |
| III | 103 | 12 | |
| IV | 3 | 1 | |
| V | 5 | 0 | |
| Recurrence | 108 (32.34%) | 5 (9.62%) | |
| Intrahepatic | 40 | 2 | |
| Extrahepatic | 64 | 3 | |
| Both | 4 | 0 | |
| Death | 113 (34.24%) | 3 (5.36%) | |
| HCC recurrence related | 69 | 2 | |
| GRWR – graft-recipient weight ratio; AST – aspartate aminotransferase; ALT – alanine aminotransferase; INR – international normalized ratio. | |||